Hyperaldosteronism Clinical Trial
Official title:
Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Background: The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional. Objective: To see if a new radioactive tracer ([68Ga]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans. Eligibility: People aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242). Design: Participants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed. Participants will have one PET scan with the study tracer. The tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes. Participants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan. Participants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.
Status | Not yet recruiting |
Enrollment | 77 |
Est. completion date | April 1, 2028 |
Est. primary completion date | December 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | - INCLUSION CRITERIA: - Must have either of the following: - one or more adrenal masses on CT and/or MRI with biochemical evidence of excess aldosterone or ACTH-independent hypercortisolism, OR - history of ACTH-dependent hypercortisolism (with or without adrenal enlargement) - Co-enrollment in 19-DK-0066, 09-C-0242, 18-CH-0031 or a similar NIH trial. - Age >=18 years. - ECOG performance status <= 2. - Women of child-bearing potential (WOCBP) and men must agree to use an effective contraception (barrier, hormonal, intrauterine device [IUD], surgical sterilization, abstinence) for two weeks prior to [68Ga]Ga-PentixaFor scan and for one week after the [68Ga]Ga-PentixaFor scan. - Breastfeeding should be discontinued for one week after the [68Ga]Ga-PentixaFor scan. - Men must agree not to donate sperm for one week after the [68Ga]Ga-PentixaFor scan. - Participants must be able to understand and willing to sign a written informed consent document. EXCLUSION CRITERIA: - Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of childbearing potential at screening. - Uncontrolled intercurrent illness or social situations based on the review of medical history that would limit compliance with study requirements. - Contraindications to having an MRI and CT. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estimate the percent concordance of [68Ga]Ga-PentixaFor imaging with clinical diagnosis in identifying functional adrenal or extra-adrenal adenomas in hyperaldosteronism and hypercortisolism | The percent concordance between [68Ga]Ga-PentixaFor and clinical diagnosis will be estimated within each Cohort, along with 90% Clopper-Pearson confidence intervals. | Screening | |
Secondary | Compare [68Ga]Ga-PentixaFor uptake to C-X-C chemokine receptor type 4 (CXCR4) expression in resected tissue (when obtained on parent protocol) | The Spearman rank correlation coefficient between [68Ga]Ga-PentixaFor PET parameters (SUVmax, SUVmean, TLU, TV) and CXCR4 expression as measured via immunohistochemistry will be estimated within each Cohort. | Within 1 year following [68Ga]Ga-PentixaFor imaging | |
Secondary | Evaluate threshold values of [68Ga]Ga-PentixaFor uptake for determining adrenal mass hyperfunction | Receiver operating characteristic (ROC) curves of [68Ga]Ga-PentixaFor SUVmax in detecting adrenal mass hyperfunction will be constructed. The cutoff associated with the highest Youden index (sensitivity plus specificity) will be selected as the optimal threshold. | Within 1 year following [68Ga]Ga-PentixaFor imaging | |
Secondary | Estimate the safety of [68Ga]Ga-PentixaFor | Safety will be evaluated by determining the frequency of adverse events among participants and reporting the results, by maximum grade of event and type of toxicity noted. | Day of [68Ga]Ga-PentixaFor administration until end of study participation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
Recruiting |
NCT02945904 -
IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
|
||
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Not yet recruiting |
NCT00553722 -
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?
|
Phase 4 | |
Completed |
NCT01234220 -
Adrenal Vein Sampling International Study (AVIS Study)
|
N/A | |
Completed |
NCT00001176 -
Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure
|
N/A | |
Active, not recruiting |
NCT04605549 -
A Study of CIN-107 in Adults With Primary Aldosteronism
|
Phase 2 | |
Not yet recruiting |
NCT03414918 -
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)
|
N/A | |
Completed |
NCT02751021 -
Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction
|
N/A | |
Recruiting |
NCT02832388 -
Primary Aldosteronism in Western Norway
|
||
Completed |
NCT00004354 -
Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
|
N/A | |
Completed |
NCT01096654 -
SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan.
|
Phase 3 | |
Completed |
NCT00155064 -
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism
|
Phase 4 | |
Recruiting |
NCT03778645 -
Adrenal Venous Sampling Via an Antecubital Approach
|
||
Recruiting |
NCT04328181 -
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
|
N/A | |
Active, not recruiting |
NCT02030587 -
Laparoscopic Adrenalectomy Versus Radiofrequency Ablation
|
N/A | |
Completed |
NCT01897727 -
Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
|
N/A | |
Recruiting |
NCT00407784 -
Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.
|
N/A | |
Recruiting |
NCT00451672 -
The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism
|
Phase 4 | |
Not yet recruiting |
NCT06192238 -
China National Study of Adrenal Venous Sampling
|